Search - tctmd.com

Displaying 1 - 20 of 103

Sort: Relevancy | Date

News Conference News ACC 2026

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

Michael O'Riordan

April 01, 2026

News Conference News ACC 2026

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

Michael O'Riordan

March 30, 2026

News Conference News ACC 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Michael O'Riordan

March 29, 2026

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

Caitlin E. Cox

March 29, 2025

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

News Conference News ACC 2024

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Michael O'Riordan

April 07, 2024

News Conference News ACC 2024

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Yael L. Maxwell

April 06, 2024

Presentation ACC 2024

Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy

Presenter: Yousuf Razvi

April 06, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

News Conference News ACC 2023

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Caitlin E. Cox

March 14, 2023

News Conference News ACC 2023

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Michael O'Riordan

March 13, 2023

News Conference News ACC 2023

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

Todd Neale

March 10, 2023

Advertisement

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

Need a Statin for Primary Prevention? There’s an App for That

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content